Antibiotics degradation products against Alzheimer’s disease
A recent paper in Cell Reports published an interesting finding: polymeric degradation products (compound X and Z, respectively) of antibiotics
Category: Drug delivery
Cyclodextrin News Year in Review 2018
The CDNews blog was created in July and after a short period of trial it started in September. During this
CASI Pharmaceuticals Announces China Market Approval Of Melphalan Hydrochloride For Injection (Trademark: EVOMELA®)
National Medical Products Administration Approves Melphalan Hydrochloride For Injection (EVOMELA®, formulation based on SBECD aka. Captisol or Dexolve) as Treatment
A “Ship-in-a-Bottle” strategy to enhance solubility and bioavailability
Metal-organic frameworks (MOFs) consisting of γ-cyclodextrin and potassium were used to incorporate folic acid clusters. The molar ratio of folic
Effect of cosolvent on the complexation of caffeic acid
Caffeic acid is a phenolic compound found in several plants and fruits including coffee beans. It has high nutraceutical value
Opinion leaders of CD society getting together in Budapest
In the recent two weeks, Cyclolab had the pleasure to welcome two prominent pioneers of cyclodextrin research, Prof. Loftsson from
NO-releasing cyclodextrins
Nitric oxide (NO) is a signaling molecule produced by almost all types of organisms ranging from bacteria to plants and
Cyclodextrins involved in clinical trials to start
According to clinicaltrials.gov, currently, there are 14 cyclodextrin-related clinical trials that in the status of i) Not yet recruiting, ii)
Sage Therapeutics Announces FDA Advisory Committee Votes 17-1 in Support of Benefit-Risk Profile of ZULRESSO™ (brexanolone) Injection for Treatment of Postpartum Depression
If approved, ZULRESSO would be the first medicine specifically indicated for the treatment of postpartum depression (PPD) Sage Therapeutics (NASDAQ:
Melinta Therapeutics Announces Positive Top-Line Results in Phase III Trial of Baxdela® (delafloxacin) for Treatment of CABP
Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, announced positive